Compare US Bancorp (USB) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Bancorp vs Vertex Pharmaceuticals Incorporated — how do they compare? US Bancorp trades at $57.12 (market cap $88.86B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and US Bancorp pays a 3.79% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold US Bancorp for 97 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| USB | VRTX | |
|---|---|---|
Market Cap | $88.86B | $127.55B |
Volume | 8,869,993 | 1,487,944 |
Sector | Financials | Health |
52-Week High | $65.42 | $557.96 |
52-Week Low | $45.28 | $407.37 |
Typical Hold Time | 97 Days | 120 Days |
Enterprise Value | $118.35B | $121.68B |
Dividend Yield | 3.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
U.S. Bancorp (USB) trades at $57.08, up 1.62% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 11.38 and net income margin of 27.61%, supported by three consecutive quarterly earnings beats. Recent news highlights dividend increases and positive Q3 2026 revenue expectations, though technical indicators suggest near-term pressure with key support at $55.
USB presents a compelling value opportunity with analyst consensus price target of $69.94 (22.5% upside) and 51% buy ratings. Risks include regulatory changes and interest rate sensitivity, but strong profitability metrics and institutional confidence support long-term growth prospects in the regional banking sector.
Vertex Pharmaceuticals (VRTX) trades at $510.08, up 0.88% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $12B revenue and $4B net income, though recent quarterly earnings show inconsistent performance against expectations. Positive Phase 2b data for inaxaplin in kidney disease highlights pipeline progress beyond cystic fibrosis dominance.
Wall Street maintains strong bullish sentiment with 84% buy ratings and $573.50 consensus target, but risks include competitive pressures and reliance on CF franchise. The stock's premium valuation (P/E 29.31) requires continued execution on pipeline expansion to justify upside potential amid technical resistance near $515.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
